Literature DB >> 14996951

Dual effects of DAMGO [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin and CTAP (D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2) on adenylyl cyclase activity: implications for mu-opioid receptor Gs coupling.

Mária Szücs1, Krisztina Boda, Alan R Gintzler.   

Abstract

The mu-opioid receptor (MOR) couples to multiple G proteins, of which coupling to Gs has long been debated. As expected, in opioid naive Chinese hamster ovary cells expressing recombinant MOR, the predominant action of [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin (DAMGO) is inhibitory. However, inactivation of Gi/Go proteins via pertussis toxin (PTX) unmasks its ability to facilitate forskolin activation of adenylyl cyclase (AC) activity. Tolerance develops to this effect of DAMGO, which can also be attenuated by cholera toxin (CTX). The latter suggests G mediation. D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 (CTAP), previously considered to be a neutral MOR antagonist, also produces a facilitation of forskolin (FSK) activation of AC that is augmented by chronic morphine. Facilitative effects of CTAP in naive as well as its augmentation in tolerant membranes are both substantially reduced by CTX. This suggests that not only Gs mediation but also G(salpha)-linked signaling is critical to the chronic morphine-induced enhanced facilitative action of CTAP. Interestingly, the (augmented) CTAP facilitation of FSK-stimulated AC activity that is observed in opioid tolerant (but not in naive) membranes is also sensitive to PTX. This can best be explained by postulating the involvement of Gi-derived G(betagamma), which would stimulate type 2 ACs, conditional on the presence of activated G(salpha). The emergence of a G(betagamma) dimension of AC stimulation by CTAP after chronic morphine could explain its ability to augment the stimulatory action of CTAP on AC. These results support putative MOR coupling to Gs and underscore the multifaceted nature and plasticity of MOR G protein coupling.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14996951     DOI: 10.1124/jpet.104.066837

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  13 in total

Review 1.  Opioid receptor trafficking and signaling: what happens after opioid receptor activation?

Authors:  Jia-Ming Bian; Ning Wu; Rui-Bin Su; Jin Li
Journal:  Cell Mol Neurobiol       Date:  2011-09-25       Impact factor: 5.046

2.  In vivo pharmacological resultant analysis reveals noncompetitive interactions between opioid antagonists in the rat tail-withdrawal assay.

Authors:  E A Walker
Journal:  Br J Pharmacol       Date:  2006-10-30       Impact factor: 8.739

3.  Structure of a Signaling Cannabinoid Receptor 1-G Protein Complex.

Authors:  Kaavya Krishna Kumar; Moran Shalev-Benami; Michael J Robertson; Hongli Hu; Samuel D Banister; Scott A Hollingsworth; Naomi R Latorraca; Hideaki E Kato; Daniel Hilger; Shoji Maeda; William I Weis; David L Farrens; Ron O Dror; Sanjay V Malhotra; Brian K Kobilka; Georgios Skiniotis
Journal:  Cell       Date:  2019-01-10       Impact factor: 41.582

4.  Molecular mechanism for opioid dichotomy: bidirectional effect of μ-opioid receptors on P2X₃ receptor currents in rat sensory neurones.

Authors:  Igor Chizhmakov; Vyacheslav Kulyk; Iryna Khasabova; Sergey Khasabov; Donald Simone; Georgy Bakalkin; Dmitri Gordienko; Alexei Verkhratsky; Oleg Krishtal
Journal:  Purinergic Signal       Date:  2015-01-16       Impact factor: 3.765

5.  Integrins regulate opioid receptor signaling in trigeminal ganglion neurons.

Authors:  K A Berg; G Zardeneta; K M Hargreaves; W P Clarke; S B Milam
Journal:  Neuroscience       Date:  2006-12-08       Impact factor: 3.590

6.  Subcellular localization of mu-opioid receptor G(s) signaling.

Authors:  Sumita Chakrabarti; Andrew Chang; Alan R Gintzler
Journal:  J Pharmacol Exp Ther       Date:  2010-01-22       Impact factor: 4.030

7.  Building a better analgesic: multifunctional compounds that address injury-induced pathology to enhance analgesic efficacy while eliminating unwanted side effects.

Authors:  T M Largent-Milnes; S W Brookshire; D P Skinner; K E Hanlon; D Giuvelis; T Yamamoto; P Davis; C R Campos; P Nair; S Deekonda; E J Bilsky; F Porreca; V J Hruby; T W Vanderah
Journal:  J Pharmacol Exp Ther       Date:  2013-07-16       Impact factor: 4.030

8.  Neutral antagonist activity of naltrexone and 6beta-naltrexol in naïve and opioid-dependent C6 cells expressing a mu-opioid receptor.

Authors:  M F Divin; F A Bradbury; F I Carroll; J R Traynor
Journal:  Br J Pharmacol       Date:  2009-02-13       Impact factor: 8.739

9.  A novel noncanonical signaling pathway for the μ-opioid receptor.

Authors:  Lei Zhang; Horace H Loh; Ping-Yee Law
Journal:  Mol Pharmacol       Date:  2013-09-23       Impact factor: 4.436

10.  Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling.

Authors:  Tally M Largent-Milnes; Wenhong Guo; Hoau-Yan Wang; Lindsay H Burns; Todd W Vanderah
Journal:  J Pain       Date:  2008-05-12       Impact factor: 5.820

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.